Loerop James (CIK 1781549) reported 16 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-02-05). Recent activity: Buy ACRS (20,875 shares), Sell ACRS (5,937 shares), Buy ACRS (11,250 shares), Buy ACRS (7,500 shares), Buy ACRS (14,750 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 20,875 | $0 |
| 2026-02-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Sell | 5,937 | $20,601 |
| 2026-02-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 11,250 | $0 |
| 2026-02-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 7,500 | $0 |
| 2026-02-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 14,750 | $0 |
| 2026-02-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Sell | 10,686 | $37,508 |
| 2026-02-03 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Sell | 15,980 | $39,630 |
| 2026-02-03 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Sell | 15,980 | $39,630 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 73,750 | $0 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Sell | 33,994 | $102,322 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 18,150 | $0 |
| 2026-01-05 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Sell | 6,171 | $17,772 |
| 2025-02-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 11,250 | $0 |
| 2025-02-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 7,500 | $0 |
| 2025-02-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Buy | 14,750 | $0 |
| 2025-02-04 | Aclaris Therapeutics, Inc. (ACRS) | Chief Business Officer | Sell | 15,447 | $38,309 |
Source: SEC Form 4 filings · as of 2026-02-05